A Study to Learn More About the Effects and Safety of JMT601 in Adults With Primary Membranous Nephropathy

This study is a multicenter, randomized, controlled, open-label, Phase Ⅱ clinical study to evaluate the efficacy, safety, Pharmacokinetics characteristics, Pharmacodynamics effects, and immunogenicity of JMT601 in participants with primary membranous nephropathy. The study has two parts. Part one is dose escalation part, and Part two is dose expansion part.

NCT Number	NCT07029139
Lead Sponsor	Shanghai JMT-Bio Inc.
Conditions	Primary Membranous Nephropathy
Enrollment	156 participants
Start Date	2025-06-30
Primary Completion	2027-04-01 (estimated)
Study Completion	2029-03-01 (estimated)
Updated on ClinicalTrials.gov	2025-06-19